Editas Medicine Inc

NASDAQ:EDIT  
32.35
-0.95 (-2.85%)
Earnings Announcements

Editas Medicine Announces Third Quarter 2021 Results

Published: 11/08/2021 12:35 GMT
Editas Medicine Inc (EDIT) - Q3 Loss per Share $0.57.
Editas Medicine - Expects Existing Cash, Cash Equivalents, Marketable Securities to Enable It to Fund Its Operating Expenses, Capex Well Into 2023.
Revenue is expected to be $4.28 Million
Adjusted EPS is expected to be -$0.72

Next Quarter Revenue Guidance is expected to be $3.71 Million
Next Quarter EPS Guidance is expected to be -$0.78

More details on our Analysts Page.